Mitochondrial genome and functional defects in osteosarcoma are associated with their aggressive phenotype

PLoS One. 2018 Dec 21;13(12):e0209489. doi: 10.1371/journal.pone.0209489. eCollection 2018.

Abstract

Osteosarcoma (OSA) is an aggressive mesenchymal tumor of the bone that affects children and occurs spontaneously in dogs. Human and canine OSA share similar clinical, biological and genetic features, which make dogs an excellent comparative model to investigate the etiology and pathogenesis of OSA. Mitochondrial (mt) defects have been reported in many different cancers including OSA, although it is not known whether these defects contribute to OSA progression and metastasis. Taking a comparative approach using canine OSA cell lines and tumor tissues we investigated the effects of mtDNA content and dysfunction on OSA biology. OSA tumor tissues had low mtDNA contents compared to the matched non-tumor tissues. We observed mitochondrial heterogeneity among the OSA cell lines and the most invasive cells expressing increased levels of OSA metastasis genes contained the highest amount of mitochondrial defects (reduced mtDNA copies, mt respiration, and expression of electron transport chain proteins). While mitochondria maintain a filamentous network in healthy cells, the mitochondrial morphology in OSA cells were mostly "donut shaped", typical of "stressed" mitochondria. Moreover the expression levels of mitochondrial retrograde signaling proteins Akt1, IGF1R, hnRNPA2 and NFkB correlated with the invasiveness of the OSA cells. Furthermore, we demonstrate the causal role of mitochondrial defects in inducing the invasive phenotype by Ethidium Bromide induced-mtDNA depletion in OSA cells. Our data suggest that defects in mitochondrial genome and function are prevalent in OSA and that lower mtDNA content is associated with higher tumor cell invasiveness. We propose that mt defects in OSA might serve as a prognostic biomarker and a target for therapeutic intervention in OSA patients.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Biomarkers, Tumor / genetics
  • Biomarkers, Tumor / isolation & purification
  • Biomarkers, Tumor / metabolism
  • Biopsy
  • Bone Neoplasms / genetics*
  • Bone Neoplasms / pathology
  • Bone Neoplasms / therapy
  • Bone Neoplasms / veterinary
  • Cancer Vaccines / therapeutic use
  • Carboplatin / therapeutic use
  • Cell Line, Tumor
  • DNA, Mitochondrial / genetics
  • DNA, Mitochondrial / isolation & purification
  • DNA, Mitochondrial / metabolism
  • Dog Diseases / genetics*
  • Dog Diseases / pathology
  • Dog Diseases / therapy
  • Dogs
  • Ethidium / toxicity
  • Genome, Mitochondrial*
  • Mitochondria / drug effects
  • Mitochondria / genetics
  • Neoplasm Invasiveness / genetics
  • Osteosarcoma / genetics*
  • Osteosarcoma / pathology
  • Osteosarcoma / therapy
  • Osteosarcoma / veterinary
  • Prognosis
  • Treatment Outcome

Substances

  • Biomarkers, Tumor
  • Cancer Vaccines
  • DNA, Mitochondrial
  • Carboplatin
  • Ethidium